Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FLR002
MIFTS: 57

Filariasis

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Filariasis

About this section

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 76 55 44 15 73
Disease Due to Superfamily Filarioidea 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 35 125.9
MeSH 44 D005368
NCIt 50 C34611
UMLS 73 C0016085
Sources

Summaries for Filariasis

About this section
Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to onchocerciasis and endomyocardial fibrosis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Albendazole and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are immune system and digestive/alimentary

Wikipedia : 76 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Sources

Related Diseases for Filariasis

About this section

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 onchocerciasis 31.9 CCL5 IL2 IL5
2 endomyocardial fibrosis 30.5 IL10 TNF
3 lichen planus 29.4 IFNG TLR9 TNF
4 uveitis 29.3 CTLA4 IFNG IL10 TNF
5 prostatitis 28.9 IL10 IL2 IL6 TNF
6 schistosomiasis 28.9 ALB IFNG IL10 IL2 IL5 TNF
7 arthritis 28.5 IFNG IL10 IL6 TNF
8 leishmaniasis 28.3 IFNG IL10 IL5 TLR2 TLR4 TLR9
9 hemorrhagic fever 27.8 ALB IFNG IL10 IL6 TNF
10 dengue hemorrhagic fever 27.8 ALB IFNG IL10 IL6 TNF
11 chagas disease 27.5 IFNG IL10 IL2 IL6 TLR2 TLR4
12 parasitic protozoa infectious disease 27.3 IFNG IL10 IL2 IL6 TLR2 TLR9
13 rheumatoid arthritis 25.5 CCL5 CTLA4 IFNG IL10 IL2 IL6
14 trypanosomiasis 24.9 ALB CCL5 IFNG IL10 IL2 IL6
15 malaria 24.1 ALB CCL5 CHIT1 CTLA4 IFNG IL10
16 filarial elephantiasis 12.3
17 loiasis 12.0
18 dirofilariasis 11.4
19 elephantiasis 11.3
20 lymphedema 11.3
21 mansonelliasis 11.2
22 podoconiosis 11.2
23 prosthetic joint infection 10.9 TLR2 TLR4
24 setariasis 10.8
25 dipetalonemiasis 10.8
26 eosinophilic fasciitis 10.8 IFNG IL5
27 hyperlucent lung 10.7 IFNG IL10
28 pouchitis 10.7 IL10 TLR4
29 fixed drug eruption 10.6 IFNG IL2
30 punctate inner choroidopathy 10.6 IL10 TNF
31 berylliosis 10.6 IFNG IL2
32 oral tuberculosis 10.6 IL2 TNF
33 tropical endomyocardial fibrosis 10.6 IL10 TNF
34 septic arthritis 10.6 IFNG TLR2 TLR4
35 variola major 10.6 IFNG IL2 TLR4
36 atopic keratoconjunctivitis 10.6 IFNG IL2 IL5
37 keratitis, hereditary 10.6 TLR2 TLR4 TLR9
38 nasal cavity disease 10.5 IL10 IL5 TLR9
39 extrapulmonary tuberculosis 10.5 IFNG IL10 TLR2
40 urinary schistosomiasis 10.5 CTLA4 IFNG IL5
41 paranasal sinus disease 10.5 IFNG IL10 IL5
42 microscopic polyangiitis 10.5 IL10 TNF
43 multifocal choroiditis 10.5 IL10 TNF
44 spondylarthropathy 10.5 TLR4 TNF
45 tungiasis 10.5 IL10 TNF
46 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5 CTLA4 IFNG IL10
47 herpes zoster 10.5 IFNG IL10 IL2
48 ige responsiveness, atopic 10.5 IFNG IL10 IL5
49 autoimmune disease of endocrine system 10.5 CTLA4 IFNG IL2
50 mycosis fungoides 10.5 CTLA4 IL2 IL5

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis
Sources

Symptoms & Phenotypes for Filariasis

About this section

MGI Mouse Phenotypes related to Filariasis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.31 IL10 FLT4 IFNG CCL5 CHIT1 CTLA4
2 digestive/alimentary MP:0005381 10.29 IL10 FLT4 IL2 ALB IFNG CTLA4
3 hematopoietic system MP:0005397 10.29 CTLA4 IL10 IFNG CCL5 IL5 TLR4
4 homeostasis/metabolism MP:0005376 10.23 CTLA4 IL10 FLT4 ALB IFNG IL5
5 cardiovascular system MP:0005385 10.18 CTLA4 IL10 FLT4 IFNG TLR2 TLR4
6 liver/biliary system MP:0005370 10.11 CTLA4 IL10 FLT4 ALB IFNG IL5
7 endocrine/exocrine gland MP:0005379 10.1 IFNG CTLA4 IL10 ALB TLR2 IL6
8 mortality/aging MP:0010768 10.06 IFNG CTLA4 IL10 FLT4 ALB TLR2
9 integument MP:0010771 10.01 CTLA4 IL10 FLT4 IFNG TLR2 TLR4
10 muscle MP:0005369 9.86 IL10 FLT4 ALB IFNG TLR4 IL6
11 neoplasm MP:0002006 9.81 IL10 ALB IFNG IL5 TLR4 IL6
12 reproductive system MP:0005389 9.61 IL10 FLT4 IFNG IL5 TLR4 IL6
13 respiratory system MP:0005388 9.28 CTLA4 IL10 IFNG IL5 TLR4 IL6
Sources

Drugs & Therapeutics for Filariasis

About this section

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54965-21-8 2082
2
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70288-86-7 6474909
3
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 90-89-1 3052
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 564-25-0 54671203
5
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 55268-74-1 4891
6
Azithromycin Approved Phase 4,Phase 2,Not Applicable 83905-01-5 55185 447043
7 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Lipoxygenase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Antimalarials Phase 4,Phase 3,Phase 2
15 Anticonvulsants Phase 4
16
Glycerol Approved, Investigational Phase 3 56-81-5 753
17
Petrolatum Approved, Investigational Phase 3 8009-03-8
18 Disinfectants Phase 3
19 Eusol Phase 3
20 Protective Agents Phase 3
21 Sodium hypochlorite Phase 3
22 Vitamins Phase 3
23 Milbemycin Phase 3,Phase 2
24
Dihydroartemisinin Approved, Investigational Phase 2 71939-50-9 6918483
25
Piperaquine Approved, Investigational Phase 2 4085-31-8 5079497
26
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
27 Artemisinine Phase 2
28 Artemisinins Phase 2
29 Anti-Asthmatic Agents Phase 2
30 Antibodies Phase 2
31 Antibodies, Monoclonal Phase 2
32 Immunoglobulins Phase 2
33 Respiratory System Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Antitubercular Agents Phase 2
36 Cytochrome P-450 CYP3A Inducers Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 2
38 Imatinib Mesylate Phase 2 220127-57-1 123596
39 Protein Kinase Inhibitors Phase 2
40
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
41 Pharmaceutical Solutions Phase 1
42
Mebendazole Approved, Vet_approved 31431-39-7 4030
43
Piperazine Approved, Vet_approved 110-85-0 4837
44
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
45
Suramin Approved, Investigational 145-63-1 5361
46
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
47 Piperazine citrate
48 Liver Extracts Not Applicable
49 Citrate Nutraceutical

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Twice Yearly Treatment for the Control of LF Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 4 Albendazole
6 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Recruiting NCT03052998 Phase 4 Ivermectin
7 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
8 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4 Praziquantel
9 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
10 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
11 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis Completed NCT02839772 Phase 3
12 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
13 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
14 A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Recruiting NCT02929134 Phase 3 Doxycycline;Placebo
16 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
17 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Not yet recruiting NCT02929121 Phase 3 Doxycycline;Placebo
18 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
19 Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Completed NCT00340691 Phase 2 Doxycycline
20 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00339417 Phase 2 Albendazole;Ivermectin
21 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00375583 Phase 2 DEC/Albendazole
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
25 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
26 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
27 Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Active, not recruiting NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
28 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
29 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
30 Relative Bioavailability Study of Emodepside IR-tablets and Solution Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
31 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
32 Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside Recruiting NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
33 Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Active, not recruiting NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
34 Exhaled NO Testing in Filariasis Completed NCT01628497
35 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
36 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
38 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
39 Research for Elim of Filariasis Completed NCT00145223
40 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
41 Interaction Between HIV and Lymphatic Filariasis Completed NCT00295698 Not Applicable Diethylcarbamazine
42 Medical Implications of Coinfection With Malaria and Filariasis Parasites Completed NCT00471666
43 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
44 Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area Completed NCT00139100 Not Applicable antimicrobial agent in soap
45 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis Completed NCT00344279
46 Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
47 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
48 Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 Not Applicable albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
49 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
50 Study of Patients With Strongyloides Stercoralis Infection Completed NCT00001245

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Sources

Genetic Tests for Filariasis

About this section
Sources

Anatomical Context for Filariasis

About this section

MalaCards organs/tissues related to Filariasis:

41
Testes, T Cells, Skin, Liver, Breast, Endothelial, B Cells
Sources

Publications for Filariasis

About this section

Articles related to Filariasis:

(show top 50) (show all 780)
# Title Authors Year
1
An assessment of mosquito collection techniques for xenomonitoring of anopheline-transmitted Lymphatic Filariasis in Ghana. ( 29898803 )
2018
2
Use of the Litomosoides sigmodontis Infection Model of Filariasis to Study Type 2 Immunity. ( 29956140 )
2018
3
Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea. ( 29224979 )
2018
4
Prevalence of and risk factors for malaria, filariasis, and intestinal parasites as single infections or co-infections in different settlements of Gabon, Central Africa. ( 29378644 )
2018
5
Bancroftian filariasis associated with male sterility. ( 29330277 )
2018
6
Understanding heterogeneities in mosquito-bite exposure and infection distributions for the elimination of lymphatic filariasis. ( 29386362 )
2018
7
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
8
Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. ( 29444078 )
2018
9
Elimination of lymphatic filariasis as a public health problem from the Cook Islands. ( 29785168 )
2018
10
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. ( 29860672 )
2018
11
Elucidation of immunological response and its regulatory network by P-TUFT-ALT-2: a promising fusion protein vaccine for human lymphatic filariasis. ( 29892388 )
2018
12
Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia. ( 29801511 )
2018
13
Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. ( 29885437 )
2018
14
Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. ( 29907117 )
2018
15
Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis. ( 29916444 )
2018
16
Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. ( 29361964 )
2018
17
Innovative Surveillance Strategies to Support the Elimination of Filariasis in Africa. ( 29958813 )
2018
18
Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. ( 29774296 )
2018
19
Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models. ( 29860286 )
2018
20
Low incidence of helminth infections (schistosomiasis, strongyloidiasis, filariasis, toxocariasis) among Dutch long-term travelers: A prospective study, 2008-2011. ( 29847574 )
2018
21
Integrated morbidity mapping of lymphatic filariasis and podoconiosis cases in 20 co-endemic districts of Ethiopia. ( 29965963 )
2018
22
<i>Carica papaya</i> (Papaya) latex: a new paradigm to combat against dengue and filariasis vectors<i>Aedes aegypti</i>and<i>Culex quinquefasciatus</i>(Diptera: Culicidae). ( 29430347 )
2018
23
Geographical distribution and species identification of human filariasis and onchocerciasis in Bioko Island, Equatorial Guinea. ( 29289559 )
2018
24
Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary? ( 29402636 )
2018
25
Human infection with sub-periodic Brugia spp. in Gampaha District, Sri Lanka: a threat to filariasis elimination status? ( 29378620 )
2018
26
Island-Wide Surveillance of Gastrointestinal Protozoan Infections on Fiji by Expanding Lymphatic Filariasis Transmission Assessment Surveys as an Access Platform. ( 29405101 )
2018
27
Green synthesis of silver nanoparticles using Holarrhena antidysenterica (L.) Wall.bark extract and their larvicidal activity against dengue and filariasis vectors. ( 29250727 )
2018
28
Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. ( 29308790 )
2018
29
Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. ( 29433461 )
2018
30
Lymphatic Endothelial Cell in Endemic Bancroftian Filariasis: A Focus on the Lymphatics of the Tunica Vaginalis Testis. ( 29861747 )
2018
31
Progress on elimination of lymphatic filariasis in Sierra Leone. ( 29866207 )
2018
32
Cervical Lymphatic Filariasis in a Pediatric Patient: Case Report and Database Analysis of Lymphatic Filariasis in the United States. ( 29848402 )
2018
33
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. ( 29943709 )
2018
34
Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. ( 29391042 )
2018
35
Acute scrotum: Hansen's disease versus filariasis. ( 29900901 )
2018
36
Mapping and modelling the impact of mass drug adminstration on filariasis prevalenceA in Myanmar. ( 29855355 )
2018
37
Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis. ( 28381279 )
2017
38
How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis. ( 28949987 )
2017
39
Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration. ( 28794687 )
2017
40
Integrated morbidity management for lymphatic filariasis and podoconiosis, Ethiopia. ( 28867846 )
2017
41
Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a <i>Loa loa</i> co-endemic area: The Angolan experience. ( 29774284 )
2017
42
Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt. ( 28785097 )
2017
43
Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis. ( 28828575 )
2017
44
Follow-up Study of Patients Previously Diagnosed with Lymphatic Filariasis in Korea. ( 29354401 )
2017
45
Imported Asymptomatic Bancroftian Filariasis Discovered from a Plasmodium vivax Infected Patient: A Case Report from Singapore. ( 28804661 )
2017
46
Subconjunctival ocular filariasis -Case report. ( 29450376 )
2017
47
Efficacy of the volatile oil from water celery (Helosciadium nodiflorum, Apiaceae) against the filariasis vector Culex quinquefasciatus, the housefly Musca domestica, and the African cotton leafworm Spodoptera littoralis. ( 28862791 )
2017
48
Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India. ( 28785847 )
2017
49
Continental-scale, data-driven predictive assessment of eliminating the vector-borne disease, lymphatic filariasis, in sub-Saharan Africa by 2020. ( 28950862 )
2017
50
Screening and evaluation of lymphatic filariasis in immigrants from endemic countries residing in a focus where it is considered eliminated in the Southern Region of Brazil: A risk of reemergence? ( 28823910 )
2017
Sources

Variations for Filariasis

About this section
Sources

Expression for Filariasis

About this section
Search GEO for disease gene expression data for Filariasis.
Sources

Pathways for Filariasis

About this section

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.04 CCL5 CHIT1 CTLA4 IFNG IL10 IL2
2
PEDF Induced Signaling 64
Show member pathways
 13.71 CCL5 FLT4 IFNG IL10 IL2 IL5
3
TGF-Beta Pathway 64
Show member pathways
 13.54 CCL5 FLT4 IFNG IL10 IL2 IL5
4
Akt Signaling 64
Show member pathways
 13.43 CCL5 FLT4 IL10 IL2 IL5 IL6
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.38 CCL5 IFNG IL10 IL2 IL5 IL6
6
PAK Pathway 64
Show member pathways
 13.33 CCL5 FLT4 IL10 IL2 IL5 IL6
7
PI3K-Akt signaling pathway 37
Show member pathways
 13.02 FLT4 IL2 IL6 TLR2 TLR4 TNF
8
Allograft rejection 1 37
Show member pathways
 12.97 CTLA4 IFNG IL10 IL2 IL5 IL6
9
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.96 CCL5 IFNG IL10 IL2 IL6 TLR1
10
IL-2 Pathway 64
Show member pathways
 12.89 IFNG IL2 TLR1 TLR2 TLR4 TLR6
11
Influenza A 37
Show member pathways
 12.88 CCL5 IFNG IL2 IL6 TLR2 TLR4
12
Pathways in cancer 37
12.85 FLT4 IFNG IL2 IL5 IL6
13
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.79 CCL5 IFNG IL6 TLR4 TNF
14
NF-KappaB Family Pathway 64
Show member pathways
 12.77 FLT4 IL2 IL6 TLR1 TLR2 TLR4
15
Regulation of IFNA signaling 66
Show member pathways
 12.73 IFNG IL10 IL2 IL5 IL6 TNF
16
Immune response IL-23 signaling pathway 22
Show member pathways
 12.64 IFNG IL10 IL2 IL6 TNF
17
TRAF Pathway 64
Show member pathways
 12.62 TLR1 TLR2 TLR4 TLR6 TLR9 TNF
18
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.56 IL6 TLR2 TLR4 TNF
19
Th17 cell differentiation 37
Show member pathways
 12.55 IFNG IL10 IL2 IL5 IL6 TLR2
20
T cell receptor signaling pathway 37
Show member pathways
 12.54 CTLA4 IFNG IL10 IL2 IL5 IL6
21
VEGF Pathway (Qiagen) 64
Show member pathways
 12.52 FLT4 TLR1 TLR2 TLR4 TLR6 TLR9
22
Antigen processing-Cross presentation 66
Show member pathways
 12.48 TLR1 TLR2 TLR4 TLR6
23
Folate Metabolism 1
Show member pathways
 12.45 ALB CCL5 IFNG IL2 IL6 TNF
24
IL-17 Family Signaling Pathways 65
Show member pathways
 12.43 IFNG IL5 IL6 TLR2 TNF
25
Diseases associated with the TLR signaling cascade 66
Show member pathways
 12.37 IL6 TLR1 TLR2 TLR4 TLR6 TLR9
26
NF-kappaB Signaling 4
12.37 CCL5 CTLA4 IFNG IL10 IL2 TLR1
27
Toxoplasmosis 37
Show member pathways
 12.36 IFNG IL10 TLR2 TLR4 TNF
28
Toll Comparative Pathway 64
Show member pathways
 12.32 IFNG IL6 TLR4 TNF
29
C-type lectin receptor signaling pathway 37
Show member pathways
 12.32 IL10 IL2 IL6 TLR9 TNF
30
Bacterial infections in CF airways 22
Show member pathways
 12.25 IFNG IL6 TLR1 TLR2 TLR4 TLR6
31
Colorectal Cancer Metastasis 64
12.22 IFNG IL6 TLR1 TLR2 TLR4 TLR6
32
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.18 CCL5 FLT4 IFNG IL10 IL2 IL5
33
Spinal Cord Injury 1
12.13 IFNG IL2 IL6 TLR4 TNF
34
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.12 IFNG IL10 IL2 IL5 IL6 TNF
35
MAPK Pathway 72
Show member pathways
 12.11 IL2 IL5 TLR1 TLR2 TLR4 TLR6
36
Amoebiasis 37
12.03 IFNG IL10 IL6 TLR2 TLR4 TNF
37
Interleukin-4 and 13 signaling 66
11.97 IL10 IL6 TNF
38
Jak-Stat Signaling Pathway 67
11.96 IFNG IL10 IL2 IL6
39
Phagocytosis of Microbes 64
11.96 TLR1 TLR2 TLR4 TLR6 TLR9
40
Rheumatoid arthritis 37
11.96 CCL5 CTLA4 IFNG IL6 TLR2 TLR4
41
TNF signaling pathway 37
11.95 CCL5 IL6 TNF
42
Glucocorticoid receptor regulatory network 1
11.92 IFNG IL2 IL5 IL6
43
Innate Lymphoid Cell Differentiation Pathways 65
11.92 IFNG IL10 IL2 IL5 TNF
44
HIF-1 signaling pathway 37
11.91 IFNG IL6 TLR4
45
Hematopoietic cell lineage 37
11.9 IL5 IL6 TNF
46
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.9 CTLA4 IFNG IL2 IL5 TNF
47
Pertussis 37
11.88 IL10 IL6 TLR4 TNF
48
Dendritic Cells Developmental Lineage Pathway 65
11.88 IFNG IL10 IL2 IL6 TLR9 TNF
49
Tuberculosis 37
11.86 IFNG IL10 IL6 TLR1 TLR2 TLR4
50
Salmonella infection (KEGG) 37
11.84 IFNG IL6 TLR4
Sources

GO Terms for Filariasis

About this section

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CTLA4 FLT4 TLR1 TLR2 TLR4 TLR6
2 extracellular space GO:0005615 9.65 ALB CCL5 CHIT1 IFNG IL10 IL2
3 membrane raft GO:0045121 9.56 TLR1 TLR2 TLR6 TNF
4 phagocytic vesicle membrane GO:0030670 9.5 TLR1 TLR2 TLR6
5 extracellular region GO:0005576 9.36 ALB CCL5 CHIT1 FLT4 IFNG IL10
6 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR1 TLR2

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.98 IL10 IL6 TLR4 TNF
2 positive regulation of DNA binding transcription factor activity GO:0051091 9.97 IL10 IL5 IL6 TNF
3 response to virus GO:0009615 9.95 CCL5 IFNG TNF
4 positive regulation of inflammatory response GO:0050729 9.95 IL2 TLR2 TLR4 TLR9
5 defense response to Gram-positive bacterium GO:0050830 9.94 IL6 TLR2 TNF
6 defense response to Gram-negative bacterium GO:0050829 9.94 IL6 TLR4 TLR9
7 positive regulation of JNK cascade GO:0046330 9.93 FLT4 TLR4 TLR9 TNF
8 regulation of insulin secretion GO:0050796 9.92 CCL5 IFNG TNF
9 response to glucocorticoid GO:0051384 9.92 IL10 IL6 TNF
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 CCL5 IFNG IL2 IL6
11 positive regulation of T cell proliferation GO:0042102 9.91 CCL5 IL2 IL6
12 humoral immune response GO:0006959 9.91 IFNG IL6 TNF
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL6 TLR2 TLR4 TLR6 TLR9 TNF
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 CCL5 IL6 TNF
15 positive regulation of tumor necrosis factor production GO:0032760 9.9 TLR2 TLR4 TLR9
16 positive regulation of interferon-gamma production GO:0032729 9.88 IL2 TLR4 TNF
17 positive regulation of JUN kinase activity GO:0043507 9.88 TLR6 TLR9 TNF
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TLR2 TLR4 TLR9 TNF
19 positive regulation of B cell proliferation GO:0030890 9.88 IL2 IL5 TLR4 TLR9
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 IFNG TLR4 TLR6 TNF
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 CCL5 TLR2 TLR4 TNF
22 positive regulation of interferon-beta production GO:0032728 9.84 TLR2 TLR4 TLR9
23 positive regulation of JAK-STAT cascade GO:0046427 9.83 CCL5 IL5 IL6
24 positive regulation of interleukin-10 production GO:0032733 9.83 TLR2 TLR4 TLR9
25 cell activation GO:0001775 9.83 TLR1 TLR2 TLR6
26 regulation of regulatory T cell differentiation GO:0045589 9.82 CTLA4 IFNG IL2
27 positive regulation of macrophage activation GO:0043032 9.81 IL10 TLR4 TLR6
28 positive regulation of interleukin-8 production GO:0032757 9.81 TLR2 TLR4 TLR9 TNF
29 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 TLR2 TLR4 TLR9
30 negative regulation of interleukin-6 production GO:0032715 9.8 IL10 TLR4 TLR9 TNF
31 positive regulation of interleukin-6 production GO:0032755 9.8 IL6 TLR2 TLR4 TLR9 TNF
32 response to molecule of bacterial origin GO:0002237 9.79 IL10 TLR2 TLR9
33 positive regulation of immunoglobulin secretion GO:0051024 9.79 IL2 IL5 IL6
34 I-kappaB phosphorylation GO:0007252 9.78 TLR2 TLR4 TLR9
35 negative regulation of B cell proliferation GO:0030889 9.77 CTLA4 IL10
36 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 IFNG TNF
37 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TLR4 TLR6
38 negative regulation of growth of symbiont in host GO:0044130 9.77 IL10 TNF
39 microglial cell activation GO:0001774 9.77 TLR2 TLR6
40 positive regulation of interleukin-8 secretion GO:2000484 9.77 TLR1 TLR2
41 toll-like receptor signaling pathway GO:0002224 9.77 TLR1 TLR2 TLR4 TLR6 TLR9
42 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.76 TLR4 TLR6
43 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 IL10 TNF
44 positive regulation of podosome assembly GO:0071803 9.76 IL5 TNF
45 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.76 TLR1 TLR4
46 cellular response to lipoteichoic acid GO:0071223 9.76 TLR2 TLR4
47 negative regulation of interleukin-17 production GO:0032700 9.76 IFNG TLR4
48 T-helper 1 type immune response GO:0042088 9.76 TLR4 TLR6
49 positive regulation of interleukin-12 production GO:0032735 9.76 IFNG TLR2 TLR4 TLR9
50 macrophage activation GO:0042116 9.75 TLR1 TLR4

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.67 TLR1 TLR2 TLR4 TLR6
2 transmembrane signaling receptor activity GO:0004888 9.65 FLT4 TLR1 TLR4 TLR6 TLR9
3 growth factor activity GO:0008083 9.62 IL10 IL2 IL5 IL6
4 lipopolysaccharide receptor activity GO:0001875 9.4 TLR2 TLR4
5 cytokine activity GO:0005125 9.17 CCL5 IFNG IL10 IL2 IL5 IL6
6 Toll-like receptor 2 binding GO:0035663 9.16 TLR1 TLR6
7 lipopeptide binding GO:0071723 9.13 TLR1 TLR2 TLR6
8 protein binding GO:0005515 10.31 ALB CCL5 CTLA4 FLT4 IFNG IL10
Sources

Sources for Filariasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....